Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial

scientific article published on 24 May 2019

Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/DOM.13757
P932PMC publication ID6771557
P698PubMed publication ID31050109

P50authorHideya MutoQ91723775
P2093author name stringYasuhiro Hashimoto
Megumi Inoue
Martin Lorenz
Roland Wesch
P2860cites workIncretin-based drugs for type 2 diabetes: Focus on East Asian perspectivesQ26749165
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesQ28254549
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effectsQ36554216
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Q37343847
iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.Q38711727
Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysisQ42202037
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-Q42703474
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemiaQ43650443
Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and CaucasiansQ44645708
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.Q51278923
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.Q51280414
P433issue8
P921main subjectinsulin glargineQ417317
type 2 diabetesQ3025883
phase I clinical trialQ5452194
P304page(s)2001-2005
P577publication date2019-05-24
P1433published inDiabetes, Obesity and MetabolismQ5270109
P1476titleEffect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial
P478volume21

Search more.